Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Forty Seven nets $81mm in public offering

Executive Summary

Oncology firm Forty Seven Inc. netted $81mm through a public offering of 10.78mm common shares (including the overallotment) at $8. Funds will support continued development of lead candidate 5F9, an anti-CD47 antibody in various clinical trials for solid and blood cancers. Earlier this month, Ono licensed exclusive rights to develop and sell 5F9 in Japan, South Korea, Taiwan, and the ASEAN countries.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies